A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT01631097
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
Tivozanib hydrochloride
Sponsor
AVEO Pharmaceuticals, Inc.